Senescence as a therapeutic target in cancer and age-related diseases
- PMID: 39548312
- DOI: 10.1038/s41573-024-01074-4
Senescence as a therapeutic target in cancer and age-related diseases
Abstract
Cellular senescence is a stress response that restrains the growth of aged, damaged or abnormal cells. Thus, senescence has a crucial role in development, tissue maintenance and cancer prevention. However, lingering senescent cells fuel chronic inflammation through the acquisition of a senescence-associated secretory phenotype (SASP), which contributes to cancer and age-related tissue dysfunction. Recent progress in understanding senescence has spurred interest in the development of approaches to target senescent cells, known as senotherapies. In this Review, we evaluate the status of various types of senotherapies, including senolytics that eliminate senescent cells, senomorphics that suppress the SASP, interventions that mitigate senescence and strategies that harness the immune system to clear senescent cells. We also summarize how these approaches can be combined with cancer therapies, and we discuss the challenges and opportunities in moving senotherapies into clinical practice. Such therapies have the potential to address root causes of age-related diseases and thus open new avenues for preventive therapies and treating multimorbidities.
© 2024. Springer Nature Limited.
Conflict of interest statement
Competing interests: J.G. has acted as a consultant for Unity Biotechnology, Geras Bio, Myricx Pharma Ltd. and Merck KGaA; owns equity in Geras Bio and share options in Myricx Pharma Ltd; is a named inventor in Medical Research Council (MRC) patents related to senolytic therapies; and has in the past received funding from Pfizer and Unity Biotechnology to work on senolytics. D.M. and J.G. are named inventors in an Imperial College patent related to senolytic therapies. I.D. declares no competing interest.
Similar articles
-
Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions.Biomolecules. 2025 Jun 13;15(6):860. doi: 10.3390/biom15060860. Biomolecules. 2025. PMID: 40563501 Free PMC article. Review.
-
Cellular senescence and senotherapeutics in cardiovascular diseases.Adv Pharmacol. 2025;104:313-349. doi: 10.1016/bs.apha.2025.01.019. Epub 2025 Feb 24. Adv Pharmacol. 2025. PMID: 40716934 Review.
-
Targeting senescent cells for the treatment of age-associated diseases.J Biochem. 2025 Mar 4;177(3):177-187. doi: 10.1093/jb/mvae091. J Biochem. 2025. PMID: 39727337 Review.
-
Senolytics: charting a new course or enhancing existing anti-tumor therapies?Cell Oncol (Dordr). 2025 Apr;48(2):351-371. doi: 10.1007/s13402-024-01018-5. Epub 2024 Dec 4. Cell Oncol (Dordr). 2025. PMID: 39633108 Free PMC article. Review.
-
New Horizons in Myotonic Dystrophy Type 1: Cellular Senescence as a Therapeutic Target.Bioessays. 2025 Mar;47(3):e202400216. doi: 10.1002/bies.202400216. Epub 2024 Dec 26. Bioessays. 2025. PMID: 39723693 Free PMC article. Review.
Cited by
-
Senescence-related cytokine levels are associated with HIV-1 serostatus and persistence.AIDS. 2025 Jul 15;39(9):1120-1124. doi: 10.1097/QAD.0000000000004204. Epub 2025 Apr 8. AIDS. 2025. PMID: 40202938
-
Is Senolytic Therapy in Cardiovascular Diseases Ready for Translation to Clinics?Biomolecules. 2025 Apr 8;15(4):545. doi: 10.3390/biom15040545. Biomolecules. 2025. PMID: 40305307 Free PMC article. Review.
-
Induced Pluripotent Stem Cells-Based Regenerative Therapies in Treating Human Aging-Related Functional Decline and Diseases.Cells. 2025 Apr 21;14(8):619. doi: 10.3390/cells14080619. Cells. 2025. PMID: 40277944 Free PMC article. Review.
-
Regulation of cellular senescence in tumor progression and therapeutic targeting: mechanisms and pathways.Mol Cancer. 2025 Apr 2;24(1):106. doi: 10.1186/s12943-025-02284-z. Mol Cancer. 2025. PMID: 40170077 Free PMC article. Review.
-
Functional Features of Senescent Cells and Implications for Therapy.Int J Mol Sci. 2025 Jun 4;26(11):5390. doi: 10.3390/ijms26115390. Int J Mol Sci. 2025. PMID: 40508198 Free PMC article. Review.
References
-
- Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614–636 (1965). - PubMed
-
- Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961). This article is a pioneering study that defines the concept of cellular senescence. - PubMed
-
- d’Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194–198 (2003). - PubMed
-
- Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997). - PubMed
-
- Chang, B. D. et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18, 4808–4818 (1999). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical